Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE No For AZ's Tagrisso Highlights Flaws of England's New Cancer Drugs Fund

Executive Summary

NICE, the HTA institute for England and Wales, has said a preliminary no to AstraZeneca PLC 's lung cancer drug Tagrisso (osimertinib). According to the firm, the decision shows that certain drugs will fare badly under NICE's new system for assessing cancer drugs.


Related Content

Tagrisso Funding Journey Shows UK’s Revamped Cancer Drugs Fund Is No Soft Touch
Positive Tagrisso Data Boost AstraZeneca's Lung Cancer Ambitions


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts